Merrill maintains Vertex at neutral

Vertex Pharmaceuticals Inc. was maintained by Merrill Lynch analyst Hari Sambasivam at a neutral rating after the company announced results of its phase 1b study of its new oral table formulation of VX-950 in combination with pegylated interferon that showed the treatment had significant hepatitis C viral reductions after just 14 days. New data for its phase 2 study of VX-950 with pegylated interferon also is expected in the first quarter. Shares of the Cambridge, Mass., pharmaceutical company were up $1.8199, or 5.82%, at $33.0999 on volume of 4,802,539 shares versus the three-month running average of 1,374,270 shares.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.